RankAlpha logo
Back to Rankings

BLFS

BioLife SolutionsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is still that BioLife has a focused recurring-revenue CGT tools model, solid Q1 growth, reaffirmed 2026 guidance, and increasing embed depth across commercial therapies and late-stage trials [#SEC-8K-2026-05-07].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
BPM represents more than 85% of revenue and the top 20 BPM customers account for about 80% of BPM sales, leaving BioLife exposed to customer concentration and program timing risk [#PR-EARNINGS-2026-05-08].
Momentum
65
Value
56
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.50 · Bull $33.00 · Bear $23.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-26 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $32.11
Why
Momentum65 · Δ7d -4.2
Value56 · Δ7d -0.2
Sentiment48 · Δ7d -7.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
65
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-23.0
Value
56
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-3.4
Why this grade

Composite grade B. Momentum 65.1 / Value 55.9 / Sentiment 48.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.42B
Beta
1.93
Shares Out
48.86M
P/E (TTM) · Derived
-93.3
P/S (TTM)
13.72
P/FCF (TTM)
3795.89
Rev YoY
+24.7%
EPS YoY
-353.7%
Gross Margin
+64.3%
Op Margin
-18.6%
Net Debt
-$71.03M
Current Ratio
7.30
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology